Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIVV001 in Type 2N and 3 Von Willebrand Disease
NCT04770935Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of efanesoctocog alfa in von Willebrand disease (VWD), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Terminal Half-Life and 5 more. Started May 2021; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT04770935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770935.